After a cancer patient dies, the cancer cells will also die. The body of the cancer patient is actually the environment and soil for the growth of the cancer cells. During the process of growth and proliferation, the cancer cells will continue to absorb the energy and nutrients from the blood of the cancer patient, and there will be a wasting away of the body, so when the supply of nutrients is interrupted after the death of the cancer patient, the cancer cells will be starved to death as well. Cancer cells are not able to survive away from the patient’s body without culture fluid. Some researchers proposed a long time ago the doctrine of using certain treatments to starve cancer cells to death. This doctrine is based on the idea that by blocking the supply of nutrients to the cancer cells, the cancer cells will not be able to continue to grow and proliferate, thus leading to the death of the cancer cells. At present, in clinical research and clinical treatment means aiming at such starvation of cancer cells are mainly anti-angiogenic treatment, and the main mechanism of anti-angiogenic drugs is to inhibit tumor neovascularization and block the blood supply of cancer, so that the cancer cells die of starvation due to lack of nutrient supply. At present, there are also some multi-targeted anti-angiogenic targeted therapeutic drugs, which on the one hand can inhibit tumor neovascularization and play the role of anti-tumor angiogenesis. On the other hand, they can inhibit the growth and proliferation of cancer cells, thus accelerating the death of cancer cells, such as Anrotinib, Sorafenib, Sunitinib, Furaquintinib, etc., which are commonly used in clinics, can play a certain anti-tumor role, but need to be used under the guidance of professional physicians.